Abivax S.A. Stock
Price
Target price
€13.48
€13.48
-3.710%
-0.52
-3.710%
-
08.05.24 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Heavy losses for Abivax S.A. today as the stock fell by -€0.520 (-3.710%).
For the coming years our community has positive and negative things to say abot the Abivax S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Valuation (undervalued/overvalued)" there were negative voices in the community.
Pros and Cons of Abivax S.A. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -3.710% | - | - | - | - | - | - |
| Valneva SE | -2.050% | -5.401% | -16.031% | -39.911% | -31.684% | -73.491% | -2.601% |
| Nanobiotix | 0.330% | 10.474% | 8.887% | 28.496% | -5.530% | -51.089% | -44.153% |
| Transgene S.A. | 0.160% | 2.381% | 5.220% | -25.087% | -3.731% | -49.412% | -57.912% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies